Novartis AG (NVSEF)
OTCMKTS · Delayed Price · Currency is USD
140.22
-6.87 (-4.67%)
At close: Jan 16, 2026
Novartis AG Employees
Novartis AG had 75,883 employees as of December 31, 2024. The number of employees decreased by 174 or -0.23% compared to the previous year.
Employees
75,883
Change (1Y)
-174
Growth (1Y)
-0.23%
Revenue / Employee
$742,880
Profits / Employee
$189,674
Market Cap
276.38B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75,883 | -174 | -0.23% |
| Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
| Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
| Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
| Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Zomedica | 152 |
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
Novartis AG News
- 1 day ago - FDA Grants Novartis Breakthrough Therapy Status To Ianalumab For Sjögren's Disease - Nasdaq
- 1 day ago - Novartis (NVS) Gains FDA Breakthrough Status for Sjögren's Disease Therapy - GuruFocus
- 1 day ago - Novartis wins FDA breakthrough status for Sjögren’s disease therapy - Seeking Alpha
- 1 day ago - Novartis (NVS) Gains FDA Breakthrough Status for Sjogren's Disease Drug - GuruFocus
- 3 days ago - Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight - Benzinga
- 4 days ago - Novartis CEO Dr. Vasant Narasimhan sits down with Jim Cramer - CNBC
- 4 days ago - Novartis (NVS) Secures License for Peptide-Based Radioligand Therapy - GuruFocus
- 4 days ago - Zonsen PepLib Biotech and Novartis Sign Worldwide License Agreement regarding Radioligand Therapy Asset - Business Wire